Editas to cut 65% of workforce in strategy shift; shelves lead gene-editing program

Andy/iStock via Getty Images Editas Medicine ( NASDAQ: EDIT ) plans to slash around 180 jobs, or approximately 65% of its workforce, over the next six months as it transitions towards becoming an in vivo company. Buoyed by recent scientific progress in its in vivo pipeline, the Massachusetts-based.